Illumina and Tempus Collaborate on Genomic AI for Precision Medicine

Illumina and Tempus have announced a collaboration to drive advancements in precision medicine through genomic AI innovation, as stated in a press release. This partnership aims to accelerate the clinical adoption of next-generation sequencing tests by combining Illumina's AI technologies with Tempus's multimodal data platform.

The collaboration will focus on generating novel evidence to support the clinical value of molecular testing across various disease categories, including cardiology, neurology, and immunology. By leveraging Tempus's comprehensive data, the initiative seeks to improve Illumina's AI-driven molecular analysis technologies, ultimately standardizing the use of genomic profiling in patient care.

This effort builds on the existing relationship between the two companies, which has previously focused on developing tools and assays to address testing needs from preemptive screening to therapy selection. The collaboration underscores a shared commitment to advancing precision medicine and improving patient outcomes through innovative genomic solutions.